A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Roche

Status: Completed

Conditions: Triple Negative Breast Carcinoma; Carcinoma, Non-Small Cell Lung; Urothelial Carcinoma; Hepatocellular Carcinoma; Small Cell Lung Carcinoma

Treatments: Drug: Atezolizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT03232593

ML39313

Details and patient eligibility

About

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

Enrollment: 1,758 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who are administered with atezolizumab for the locally approved indications

Exclusion criteria

• Participants with a known hypersensitivity to atezolizumab or to any of the excipients

Trial design

1,758 participants in 1 patient group

Participants who Receive Atezolizumab

Description:

Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.

Treatment:

Drug: Atezolizumab